<unk> , sold under the brand names Jakafi and Jakavi, is a medication for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow; polycythemia vera (PCV), when there has been an inadequate response to or intolerance of hydroxyurea; and steroid-refractory acute graft-versus-host disease. It was developed and marketed by Incyte Corp in the US under the brand name Jakafi, and by Novartis elsewhere in the world, under the brand name Jakavi.<unk>  is a janus kinase inhibitor. In September 2021,<unk>  cream (sold under the brand name Opzelura) was approved for medical use in the United States for the treatment of mild to moderate atopic dermatitis (AD). It is the first topical janus kinase inhibitor approved in the United States.
Ruxolitinib
Ibrutinib
Bosutinib
Imatinib
Ranibizumab
Abrocitinib
Ceritinib
Ponatinib